Cited 39 times in
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 김경아 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김명진 | - |
dc.contributor.author | 김범경 | - |
dc.date.accessioned | 2014-12-18T08:46:26Z | - |
dc.date.available | 2014-12-18T08:46:26Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86926 | - |
dc.description.abstract | PURPOSES: To date, most studies about the optimal number of target lesions for enhancement criteria for hepatocellular carcinoma (HCC) have focused on cross-sectional analyses of concordance. We investigated the optimal number of target lesions for European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS). EXPERIMENTAL DESIGN: We analyzed 254 consecutive treatment-naïve patients with HCC having at least 2 measurable target lesions undergoing transarterial chemoembolization. Kappa values for intermethod agreement of treatment responses were calculated for comparisons between use of maximum of 1, 2, 3, 4, or 5 targets versus use of all target lesions. Prognostic values of radiologic assessments according to number of target lesions for predicting OS were expressed as C-index. RESULTS: By EASL and mRECIST guidelines, κ values between responses assessing the longest 2, 3, 4, or 5 targets and assessing all targets were 0.924, 0.977, 1.000, or 1.000 and 0.907, 0.959, 1.000, or 1.000, respectively, whereas those between responses assessing only one target and assessing all target lesions were 0.723 and 0.666, respectively. C-index when measuring the longest 1, 2, 3, 4, 5, and all targets was similar, ranging from 0.739 to 0.749 for EASL criteria and from 0.750 to 0.759 for mRECIST. From Cox regression analyses, radiologic response from each calculation method showed independently significant effects on OS for both guidelines, regardless of number of target lesions. CONCLUSIONS: Prognostic values for predicting OS were similar regardless of number of target lesions. Assessing the 2 largest targets rather than only 1 index lesion could be recommended considering high concordances from cross-sectional analyses. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Carcinoma, Hepatocellular/diagnosis | - |
dc.subject.MESH | Carcinoma, Hepatocellular/epidemiology* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/pathology | - |
dc.subject.MESH | Chemoembolization, Therapeutic | - |
dc.subject.MESH | Europe | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Guidelines as Topic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/diagnosis | - |
dc.subject.MESH | Liver Neoplasms/epidemiology* | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Survival Analysis* | - |
dc.title | Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학) | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Myeong-Jin Kim | - |
dc.contributor.googleauthor | Kyung Ah Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-12-2721 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00426 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00301 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 23225115 | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Carcinoma, Hepatocellular/diagnosis | - |
dc.subject.keyword | Carcinoma, Hepatocellular/epidemiology* | - |
dc.subject.keyword | Carcinoma, Hepatocellular/pathology | - |
dc.subject.keyword | Chemoembolization, Therapeutic | - |
dc.subject.keyword | Europe | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Guidelines as Topic* | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Liver Neoplasms/diagnosis | - |
dc.subject.keyword | Liver Neoplasms/epidemiology* | - |
dc.subject.keyword | Liver Neoplasms/pathology | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Proportional Hazards Models | - |
dc.subject.keyword | Survival Analysis* | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Kim, Kyung Ah | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Myeong Jin | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Myeong Jin | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Ah | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 19 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1503 | - |
dc.citation.endPage | 1511 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.19(6) : 1503-1511, 2013 | - |
dc.identifier.rimsid | 32038 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.